We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

17 hedge funds and large institutions have $755K invested in Finch Therapeutics Group, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

6% less funds holding

Funds holding: 18 → 17 (-1)

45% less capital invested

Capital invested by funds: $1.37M → $755K (-$614K)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.3K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$11.1K
3
TRCT
Tower Research Capital (TRC)
New York
+$8.63K
4
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
+$556
5
Morgan Stanley
Morgan Stanley
New York
+$485

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$26.5K
2
AA
Ancora Advisors
Ohio
-$2.76K
3
SPIA
Steward Partners Investment Advisory
New York
-$389
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$243K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$213K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$140K +$11.1K +2,825 +8%
LSAG
4
Lake Street Advisors Group
New Hampshire
$76.6K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$42K +$46.3K +11,746 New
IC
6
Ikarian Capital
Texas
$24.9K – – –
TRCT
7
Tower Research Capital (TRC)
New York
$9.48K +$8.63K +2,187 +498%
BL
8
Bleichroeder LP
New York
$3.5K – – –
BlackRock
9
BlackRock
New York
$1.23K – – –
Morgan Stanley
10
Morgan Stanley
New York
$888 +$485 +123 +100%
Northwestern Mutual Wealth Management
11
Northwestern Mutual Wealth Management
Wisconsin
$509 +$556 +141 New
Bank of America
12
Bank of America
North Carolina
$43 +$47 +12 New
Wells Fargo
13
Wells Fargo
California
$22 – – –
MFT
14
Moisand Fitzgerald Tamayo
Florida
$11 – – –
UBS Group
15
UBS Group
Switzerland
$7 – – –
MP
16
MSD Partners
New York
– -$26.5K -5,113 Closed
AA
17
Ancora Advisors
Ohio
– -$2.76K -533 Closed
SPIA
18
Steward Partners Investment Advisory
New York
– -$389 -75 Closed

FNCH Hedge Fund Activity: Q4 2023 in Review

17 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q4 2023, worth a combined $755K — down 45% from $1.37M a quarter earlier.

Fund positioning in FNCH was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46.3K. The largest seller was MSD Partners, exiting entirely with an estimated $26.5K sold.

  • 17 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q4 2023, down from 18 in Q3 2023.
  • Funds reported $755K of Finch Therapeutics Group, Inc. Common Stock stock for Q4 2023, down 45% quarter-over-quarter.
  • 3 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of 0 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q4 2023 was Renaissance Technologies, an estimated $46.3K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q4 2023 was MSD Partners, an estimated $26.5K sold.

Based on aggregated 13F filings for Q4 2023.